Vivus (VVUS) falls after releasing new safety data related to its proposed diet drug Qnexa. The...

|By:, SA News Editor

Vivus (VVUS) falls after releasing new safety data related to its proposed diet drug Qnexa. The company's analysis found that one ingredient, which is also used in an anti-seizure drug, was associated with higher rate of cleft palates in offspring of women who took the drug during pregnancy, compared with a control group. Shares -6.3% AH.